Safety and efficacy of intensive vs. guideline antiplatelet therapy in high-risk patients with recent ischemic stroke or transient ischemic attack: Rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388)

International Journal of Stroke

Volumn 10, Issue 7, 2015, Pages 1159-1165

  Bath, Philip ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Acute stroke; Aspirin; Clopidogrel; Dipyridamole; Randomized controlled trial; Transient ischemic attack

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT;

ANTICOAGULANT THERAPY; ARTICLE; BRAIN ISCHEMIA; COGNITION; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GUIDELINE ANTIPLATELET THERAPY; HUMAN; INTENSIVE ANTIPLATELET THERAPY; INTERMETHOD COMPARISON; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MOOD; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SINGLE BLIND PROCEDURE; TRANSIENT ISCHEMIC ATTACK; AGE; AGED; CLINICAL TRIAL; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; INTERNATIONAL COOPERATION; ISCHEMIC ATTACK, TRANSIENT; MALE; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; STANDARDS; STROKE; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL COOPERATION; ISCHEMIC ATTACK, TRANSIENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PLATELET AGGREGATION INHIBITORS; RESEARCH DESIGN; STROKE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84942292531     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12538     Document Type: Article

References (61)

1. Rothwell PM, Giles MF, Chandratheva A etal. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (express study): a prospective population-based sequential comparison. Lancet Neurol 2007; 370:1432-1442.
2. Lavallee PC, Meseguer E, Abboud H etal. A transient ischaemic attach clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol 2007; 6:953-960.
3. Johnson SC, Leira EC, Hansen MD, Adams HPJ. Early recovery after cerebral ischemia risk of subsequent neurological deterioration. Ann Neurol 2003; 54:439-444.
4. Johnson SC, Easton JD. Are patients with acutely recovered cerebral ischemia more unstable? Stroke 2003; 34:2446-2450.
5. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J 1995; 108:710-717.
6. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
7. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and the secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003; 34:2741-2749.
8. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363:757-767.
9. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-559.
10. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJM, for the Carotid Endarterectomy Trialists Collaboration. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004; 363:915-924.
11. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after TIA or minor stroke. Lancet 1993; 342:1255-1262.
12. Diener HC, Connolly SJ, Ezekowitz MD etal. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the re-ly trial. Lancet Neurol 2010; 9:1157-1163.
13. Hankey GJ, Patel MR, Stevens SR etal. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11:315-322.
14. Easton JD, Lopes RD, Bahit MC etal. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11:503-511.
15. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54:1044-1054.
16. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30mg vs. 283mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325:1261-1266.
17. International Stroke Trial Collaborative Group. The international stroke trial (ist); a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349:1569-1581.
18. CAST (Chinese Acute Stroke Trial) Collaborative Group. Cast: randomised placebo-controlled trial of early aspirin use in 20000 patients with acute ischaemic stroke. Lancet 1997; 349:1641-1649.
19. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:1-13.
20. Leonardi-Bee J, Bath PM, Bousser MG etal. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 2005; 36:162-168.
21. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367:1665-1673.
22. Halkes PH, Gray LJ, Bath PM etal. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. J Neurol Neurosurg Psychiatry 2008; 79:1218-1223.
23. Wang Y, Wang Y, Zhao X etal. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369:11-19.
24. Kennedy J, Hill MD, Ryckborst K etal. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6:961-969.
25. Dengler R, Diener HC, Schwartz A etal. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24h of symptom onset (early trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010; 9:159-166.
26. Bath PM, Cotton D, Martin RH etal. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: profess subgroup analysis. Stroke 2010; 41:732-738.
27. Geeganage CM, Diener H-C, Algra A etal. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack. Stroke 2012; 43:1058-1066.
28. Wong KSL, Wang Y, Leng X etal. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation 2013; 128:1656-1666.
29. Michelson AD, Cattaneo M, Eikelboom JW etal. Aspirin resistance: position paper of the working group on aspirin resistance. J Thromb Haemost 2005; 3:1309-1311.
30. Siller-Matula J, Schror K, Wojta J, Huber K. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97:385-393.
31. Serebruany V, Cherala G, Williams C etal. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of 'resistance'. Am Heart J 2009; 158:925-932.
32. Bhatt DL, Fox KAA, Werner Hacke CB etal. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706-1717.
33. Diener HC, Bogousslavsky J, Brass LM etal. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (match): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:331-337.
34. Bath PMW. Role of aspirin in match. Lancet 2004; 364:1662.
35. Zhao L, Bath P, Heptinstall S. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. Br J Pharmacol 2001; 134:353-358.
36. Scholz T, Zhao L, Temmler U, Bath P, Heptinstall S, Losche W. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro. Platelets 2002; 13:401-406.
37. Zhao L, Bath PMW, Fox S etal. The effects of GPII-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions. Curr Med Res Opin 2003; 19:178-186.
38. Zhao L, Fletcher S, Weaver C etal. Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and lecokyte function in normal volunteers and patients with prior ischaemic stroke. Thromb Haemost 2005; 93:527-534.
39. Zhao L, Gray LJ, Leonardi-Bee J, Weaver CS, Heptinstall S, Bath PM. Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. Platelets 2006; 17:100-104.
40. Sprigg N, Gray LJ, England T etal. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. PLoS ONE 2008; 3:e2852.
41. Willmot M, Zhao L, Heptinstall S, Bath PMW. Triple antiplatelet therapy for secondary prevention of recurrent ischemic stroke. J Stroke Cerebrovasc Dis 2004; 13:138-140.
42. Bath P, Robson K, Woodhouse L, Sprigg N, Dineen R, Pocock S. Statistical analysis plan for the 'triple antiplatelets for reducing dependency after ischaemic stroke' (TARDIS) trial. Int J Stroke 2015; 10:449-451.
43. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural-history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337:1521-1526.
44. Adams HP, Davis PH, Leira EC etal. Baseline NIH stroke scale score strongly predicts outcome after stroke. A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999; 53:126-131.
45. Wardlaw JM, Sellar R. A simple practical classification of cerebral infarcts on ct and its interobserver reliability. Am J Neuroradiol 1994; 15:1933-1939.
46. Barber PA, Demchuk AM, Zhang JJ, Buchan AM, Group AS. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet 2000; 355:1670-1674.
47. Sandercock P, Wardlaw JM, Lindley RI etal. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet 2012; 379:2352-2363.
48. Bath P, Woodhouse L, Scutt P etal. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. Lancet 2015; 385:617-628.
49. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337:1521-1526.
50. Weir CJ, Lees KR. Comparison of stratification and adaptive methods for treatment allocation in an acute stroke clinical trial. Stat Med 2003; 22:705-726.
51. Anonymous . The international stroke trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997; 349:1569-1581.
52. Yusuf S, Fox KAA, Tognoni G etal. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. NEJM 2001; 345:494-502.
53. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European stroke prevention study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:1-13.
54. Stewart K, Walters M, Dawson J. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (NICE technology appraisal guidance 90). Heart 2011; 97:585-586.
55. Hallas J, Dall M, Andries A etal. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333:726.
56. Brooks R. Euroqol: the current state of play. Health Policy (New York) 1996; 37:53-72.
57. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965; 12:63-70.
58. Bath PMW, Geeganage CM, Gray LJ, Collier T, Pocock S. Use of ordinal outcomes in vascular prevention trials: comparison with binary outcomes in published stroke trials. Stroke 2008; 39:2817-2823.
59. Weaver CS, Leonardi-Bee J, Bath-Hextall FJ, Bath PMW. Sample size calculations in acute stroke trials: a systematic review of their reporting, characteristics, and relationship with outcome. Stroke 2004; 35:1216-1224.
60. The Optimising Analysis of Stroke Trials (OAST) Collaboration. Calculation of sample size for stroke trials assessing functional outcome: comparison of binary and ordinal approaches. Int J Stroke 2008; 3:78-84.
61. The Optimising Analysis of Stroke Trials (OAST) Collaboration. Should stroke trials adjust functional outcome for baseline prognostic factors? Stroke 2009; 40:888-894.